語系/ Language:
繁體中文
English
KMU OLIS
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Complete accounts of integrated drug...
~
Abdel-Magid, Ahmed F., (1947-)
Complete accounts of integrated drug discovery and development.recent examples from the pharmaceutical industry /. Volume 1 :
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Complete accounts of integrated drug discovery and development./ Ahmed F. Abdel-Magid, editor, Therachem Research Medilab, LLC, Chelsea, Alabama, United States, Jaan A. Pesti, editor, EnginZyme AB, Stockholm, Sweden, Rajappa Vaidyanathan, editor, Bristol-Myers Squibb, Bangalore, India ; sponsored by the ACS Division of Organic Chemistry.
其他題名:
recent examples from the pharmaceutical industry /
其他作者:
Vaidyanathan, Rajappa,
面頁冊數:
1 online resource (314 pages) :illustrations (some color). :
附註:
Distributed in print by Oxford University Press.
標題:
MEDICAL / Research. -
電子資源:
https://pubs.acs.org/doi/book/10.1021/bk-2018-1307
ISBN:
9780841233966
Complete accounts of integrated drug discovery and development.recent examples from the pharmaceutical industry /. Volume 1 :
Complete accounts of integrated drug discovery and development.
recent examples from the pharmaceutical industry /Volume 1 :Ahmed F. Abdel-Magid, editor, Therachem Research Medilab, LLC, Chelsea, Alabama, United States, Jaan A. Pesti, editor, EnginZyme AB, Stockholm, Sweden, Rajappa Vaidyanathan, editor, Bristol-Myers Squibb, Bangalore, India ; sponsored by the ACS Division of Organic Chemistry. - 1 online resource (314 pages) :illustrations (some color). - ACS symposium series,13071947-5918 ;. - ACS symposium series ;1014..
Distributed in print by Oxford University Press.
Includes bibliographical references and index.
Discovery and Development of GDC-0994: A Selective and Efficacious Small Molecule Inhibitor of ERK1/2 /Linghu, Xin, Ideaya Biosciences, 7000 Shoreline Ct Suite 350, South San Francisco, California 94080-4990, United States; Wong, Nicholas, Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States; Blake, James F., Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States; Gaudino, John J., Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States; Moffat, John G., Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States /http://dx.doi.org/10.1021/bk-2018-1307.ch001 --
ISBN: 9780841233966
Standard No.: bk-2018-1307Subjects--Topical Terms:
469015
MEDICAL / Research.
LC Class. No.: RM301.25 / .C66 2018 v.1
Dewey Class. No.: 615.1/9
National Library of Medicine Call No.: QV 745 / C736 2018
Complete accounts of integrated drug discovery and development.recent examples from the pharmaceutical industry /. Volume 1 :
LDR
:06480nam a2200325 i 4500
001
339745
006
m o d
007
cr*cn ---unuuu
008
210625s2018 dcua ob 101 0 eng d
020
$a
9780841233966
$q
electronic
024
8
$a
bk-2018-1307
035
$a
ccn00862473
040
$a
NjRocCCS
$b
eng
$e
rda
$c
NjRocCCS
050
4
$a
RM301.25
$b
.C66 2018 v.1
060
4
$a
QV 745
$b
C736 2018
082
0 4
$a
615.1/9
$2
23
084
$a
MED071000
$a
MED106000
$2
bisacsh
245
0 0
$a
Complete accounts of integrated drug discovery and development.
$p
Volume 1 :
$b
recent examples from the pharmaceutical industry /
$c
Ahmed F. Abdel-Magid, editor, Therachem Research Medilab, LLC, Chelsea, Alabama, United States, Jaan A. Pesti, editor, EnginZyme AB, Stockholm, Sweden, Rajappa Vaidyanathan, editor, Bristol-Myers Squibb, Bangalore, India ; sponsored by the ACS Division of Organic Chemistry.
264
1
$a
Washington, DC :
$b
American Chemical Society,
$c
2018.
300
$a
1 online resource (314 pages) :
$b
illustrations (some color).
336
$a
text
$2
rdacontent
337
$a
computer
$2
rdamedia
338
$a
online resource
$2
rdacarrier
490
1
$a
ACS symposium series,
$x
1947-5918 ;
$v
1307
500
$a
Distributed in print by Oxford University Press.
504
$a
Includes bibliographical references and index.
505
0 0
$t
Discovery and Development of GDC-0994: A Selective and Efficacious Small Molecule Inhibitor of ERK1/2 /
$r
Linghu, Xin, Ideaya Biosciences, 7000 Shoreline Ct Suite 350, South San Francisco, California 94080-4990, United States; Wong, Nicholas, Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States; Blake, James F., Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States; Gaudino, John J., Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States; Moffat, John G., Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch001 --
$t
Preclinical Identification and Development of AM-6138: An Inhibitor of BACE1 for the Treatment of Alzheimer’s Disease /
$r
Mennen, Steven M., Process Development, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States; Stellwagen, John, Department of Medicinal Chemistry, Amgen Discovery Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States; White, Ryan D., Department of Medicinal Chemistry, Amgen Discovery Research, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch002 --
$t
Discovery and Chemical Development of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer’s Disease /
$r
Thaisrivongs, David A., Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States; Morris, William J., Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States; Scott, Jack D., Discovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch003 --
$t
Discovery and Chemical Development of JNJ-50138803, a Clinical Candidate BACE1 Inhibitor /
$r
Gijsen, Harrie J. M., Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium; Lin, Jinguang, STA Pharmaceuticals, A WuxiApptec Company, 589 N. Yulong Rd., Changzhou, 213127, China; Houpis, Yannis, Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch004 --
$t
Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections /
$r
Tong, Ling, Discovery Chemistry, MRL, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States; Kozlowski, Joseph A., Discovery Chemistry, MRL, Merck & Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States; Campeau, Louis-Charles, Process Research & Development, MRL, Merck & Co., Inc., 126 East Lincoln Ave., P.O. Box 2000, Rahway, New Jersey 07065, United States; Yin, Jingjun, Process Research & Development, MRL, Merck & Co., Inc., 126 East Lincoln Ave., P.O. Box 2000, Rahway, New Jersey 07065, United States /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch005 --
$t
AZD6564, Discovery of a Potent 5-Substituted Isoxazol-3-ol Fibrinolysis Inhibitor and Development of an Enantioselective Large-Scale Route for Its Preparation /
$r
Karlsson, Staffan, Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, SE-431 83 Gothenburg, Sweden; Pettersen, Daniel, Medicinal Chemistry, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, SE-431-83 Gothenburg, Sweden; Sörensen, Henrik, Medicinal Chemistry, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, SE-431-83 Gothenburg, Sweden /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch006 --
$t
Design and Development of the Glucokinase Activator AZD1656 /
$r
McKerrecher, Darren, Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Darwin Building, Unit 310, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, United Kingdom; Steven, Alan, Pharmaceutical Technology & Development, AstraZeneca, Charter Way, Macclesfield, SK10 2NA, United Kingdom /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch007 --
$t
Development of a Reversible P2Y12R Antagonist, AZD1283—Discovery Research and Large-Scale Chemistry /
$r
Zetterberg, Fredrik, Galecto Biotech AB, Sahlgrenska Science Park, Medicinaregatan 8 A, S-413 46 Gothenburg, Sweden; Aurell, Carl-Johan, Carl-Johan Aurell, AstraZeneca R&D Gothenburg, Pharmaceutical Sciences, Early Chemical Development, Large Scale Chemistry, SE-43183 Mölndal, Sweden /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch008 --
$t
Discovery, Process Development, and Scale-Up of a Benzoxazepine-Containing mTor Inhibitor /
$r
Leahy, James W.; Naganathan, Sriram; Andersen, Denise L.; Andersen, Neil G.; Lau, Stephen /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ch009 --
$t
Editors’ Biographies /
$u
http://dx.doi.org/10.1021/bk-2018-1307.ot001
588
$a
Description based on publisher-supplied information and home-page.
590
$a
American Chemical Society, ACS Symposium Series eBooks - 2018 Front Files.
650
7
$a
MEDICAL / Research.
$2
bisacsh
$3
469015
650
7
$a
MEDICAL / Pharmacology.
$2
bisacsh
$3
450489
650
1 2
$a
TOR Serine-Threonine Kinases
$x
antagonists & inhibitors.
$3
469014
650
1 2
$a
Oxazepines.
$3
469013
650
1 2
$a
Glucokinase.
$3
469012
650
1 2
$a
Fibrinolysis.
$3
469011
650
1 2
$a
Hepacivirus.
$3
469010
650
1 2
$a
Alzheimer Disease
$x
drug therapy.
$3
469009
650
1 2
$a
Amyloid Precursor Protein Secretases
$x
antagonists & inhibitors.
$3
469008
650
1 2
$a
Extracellular Signal-Regulated MAP Kinases
$x
antagonists & inhibitors.
$3
469007
650
1 2
$a
Drug Development.
$3
464503
650
1 2
$a
Drug Discovery.
$3
301877
650
0
$a
Rapamycin
$x
Chemical inhibitors
$x
Development.
$3
469006
650
0
$a
Purines
$x
Receptors
$x
Antagonists
$x
Development.
$3
469005
650
0
$a
G proteins
$x
Antagonists
$x
Development.
$3
469004
650
0
$a
Glucokinase
$x
Regulation
$x
Development.
$3
469003
650
0
$a
Fibrinolysis
$x
Chemical inhibitors
$x
Development.
$3
469002
650
0
$a
Hepatitis C virus
$x
Treatment
$x
Technological innovations.
$3
469001
650
0
$a
Membrane proteins
$x
Chemical inhibitors
$x
Development.
$3
469000
650
0
$a
Alzheimer's disease
$x
Treatment
$x
Technological innovations.
$3
468999
650
0
$a
Protein kinases
$x
Chemical inhibitors
$x
Development.
$3
468998
650
0
$2
96060
$a
Pharmaceutical technology.
$3
254322
650
0
$2
96060
$a
Pharmaceutical industry.
$3
253879
650
0
$2
96060
$a
Drug development.
$3
232902
700
1
$a
Vaidyanathan, Rajappa,
$e
editor.
$u
Bristol-Myers Squibb, Bangalore, India.
$3
468996
700
1
$a
Pesti, Jaan A.,
$d
1954-
$e
editor.
$u
EnginZyme AB, Stockholm, Sweden.
$3
468995
700
1
$a
Abdel-Magid, Ahmed F.,
$d
1947-
$e
editor.
$u
Therachem Research Medilab, LLC, Chelsea, Alabama, United States.
$3
468994
710
2
$a
American Chemical Society.
$b
Division of Organic Chemistry,
$e
sponsoring body.
$3
468997
776
1
$c
Original
$z
9780841233980 (alk. paper)
830
0
$a
ACS symposium series ;
$v
1014.
$3
311094
856
4
$3
ACS
$u
https://pubs.acs.org/doi/book/10.1021/bk-2018-1307
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得,請勿在此評論區張貼涉及人身攻擊、情緒謾罵、或內容涉及非法的不當言論,館方有權利刪除任何違反評論規則之發言,情節嚴重者一律停權,以維護所有讀者的自由言論空間。
Export
取書館別
處理中
...
變更密碼
登入